- Home
- IMUX vs ANVS Comparison
IMUX vs ANVS Comparison
Compare IMUX & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMUX | ANVS |
|---|---|---|
| Founded | 2016 | 2008 |
| Country | United States | United States |
| Employees | 66 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.2M | 111.3M |
| IPO Year | 2013 | 2019 |
Fundamental Metrics
Financial Performance| Metric | IMUX | ANVS |
|---|---|---|
| Price | $1.26 | $2.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $4.25 | ★ $13.50 |
| AVG Volume (30 Days) | ★ 4.9M | 314.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 38.00 | ★ 62.92 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.51 | $1.11 |
| 52 Week High | $1.35 | $5.50 |
Technical Indicators
Market Signals| Indicator | IMUX | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 74.69 | 46.37 |
| Support Level | $0.61 | $2.27 |
| Resistance Level | N/A | $2.63 |
| Average True Range (ATR) | 0.10 | 0.20 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 93.20 | 33.85 |
Price Performance
Historical ComparisonAbout IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.